Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Opportunity Assessment of the Global Nasal Drug Delivery Technology Market, 2019-2025 - ResearchAndMarkets.com

March 6, 2019

DUBLIN--(BUSINESS WIRE)--Mar 6, 2019--The “Nasal Drug Delivery Technology Market Analysis Report By Therapeutic Application (Asthma, Rhinitis), By Dosage Form (Powder, Gel, Spray, Drops), By Container Type, And Segment Forecasts, 2019 - 2025” report has been added to ResearchAndMarkets.com’s offering.

The global nasal drug delivery systems market size is expected to reach USD 67.99 billion by 2025 expanding at 6.5% CAGR.

Rising awareness about nasal products is one of the major factors driving the market. Growing geriatric population is also expected to have positive impact on the market.

According to the United Nations Department of Economic and Social Affairs, the global geriatric population (60 years and above), was around 962 million in 2017. The number is expected to grow, particularly in Latin America with 71% rise in population aged 60 and over, followed by Asia (66%), Africa (64%), North America (41%), and Europe (23%).

Moreover, ongoing product development and their expected commercialization will propel market growth over the forecast period. For instance, In April 2018, Dr. Reddy’s Laboratories, along with its subsidiary Promius Pharma, LLC, announced filing of their New Drug Application (NDA) for DFN-02, for the treatment of migraine.

Increasing adoption of self-administration practices and focus on other alternative routes of drug delivery, such as nasal drug delivery, also offer growth opportunities for the market.

Some of the key companies in the industry are AstraZeneca PLC; OptiNose, Inc.; Pfizer, Inc.; Becton, Dickinson and Company; Promius Pharma LLC; B.F. Ascher & Company, Inc.; and Cadila Pharmaceuticals Ltd.

Further key findings from the study suggest:

Topics Covered

Chapter 1 Methodology and Scope

1.1 Research Methodology

1.2 Research Scope and Assumptions

1.3 List of Tables

Chapter 2 Executive Summary

2.1 Market Summary

Chapter 3 Market Variables, Trends & Scope

3.1 Market Segmentation

Chapter 4 Market Definitions

Chapter 5 Industry Outlook

5.1 Market Variable Analysis

5.1.1 Increasing preference for nasal drug delivery technology

5.1.2 Growing incidence of chronic diseases

5.1.3 Growing geriatric population

5.2 Market Restraint Analysis

5.2.1 Complications associated with the overuse of nasal powders

Chapter 6 Business Environment Analysis

6.1 SWOT Analysis; By factor (Political & legal, economic and technological)

6.2 Porter’s Five Forces Analysis

Chapter 7 Dosage Forms Business Analysis

7.1 Nasal Drug Delivery Technology market: Dosage Forms Movement Analysis

7.2 Nasal Spray

7.3 Nasal Drop

7.4 Nasal Gel

7.5 Nasal Powder

Chapter 8 Container Type Business Analysis

8.1 Nasal Drug Delivery Technology market: Container Type Movement Analysis

8.2 Pressurized container

8.3 Pressurized container market estimates and forecast, 2014 - 2025

8.4 Non-pressurized container

8.5 Non-pressurized container market estimates and forecast, 2014 - 2025

Chapter 9 Therapeutic Application Business Analysis

9.1 Nasal Drug Delivery Technology market: Therapeutic Application Movement Analysis

9.2 Nasal Congestion

9.3 Rhinitis

9.4 Asthma

9.5 Others

Chapter 10 Regional Business Analysis

10.1 Nasal Drug Delivery Technology Market: Regional Movement Analysis

10.2 North America

10.3 Europe

10.4 Asia-Pacific

10.5 Latin America

10.6 Middle East and Africa

Chapter 11 Company Profiles

11.1 Company Profiles

11.1.1 GlaxoSmithkline PLC

11.1.2 AstraZeneca

11.1.3 Pfizer Inc.

11.1.4 OptiNose

11.1.5 Becton, Dickson and Company

11.1.6 Promius Pharma

11.1.7 B.F. Ascher & Company Inc.

11.1.8 Cadila Pharmaceuticals

11.1.9 Douglas NZ

11.1.10 ENT Technologies Pty. Ltd.

11.1.11 Pendopharm

11.1.12 NAVEH Pharma

For more information about this report visit https://www.researchandmarkets.com/research/2t5v4s/opportunity?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190306005526/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Transdermal and Transmucosal Drug Delivery



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 03/06/2019 10:42 AM/DISC: 03/06/2019 10:42 AM


All contents © copyright 2019 The Associated Press. All rights reserved.